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< W2. Th us, case (1) is viable, provided 
that the endothelium is intrinsically more 
selective than the epithelium (that is, has 
a higher σ or lower W).
For case (2), the very complicated 
expression that results makes it diffi  cult 
to draw general conclusions. Some pos-
sibilities are illustrated in Figure 1, in 
which θ is shown as a function of Pe for 
Pe = Pe1 = Pe2. Th ree combinations of 
W1 and W2 are considered, with W1W2 = 
0.01 in each. If the two layers are the same 
(W1 = W2), then θ decreases monotoni-
cally with increasing Pe (or GFR), as for 
a simple membrane of double thick-
ness and as in Figure 5 of Rippe et al.1 
Likewise, θ decreases monotonically if 
the upstream layer is much more selec-
tive (W1 << W2). In either situation, the 
minimum for θ equals W1; that is, the 
composite is no more selective than the 
upstream layer. For a much more selec-
tive downstream layer (W1 >> W2), the 
behavior is more complicated, with θ fi rst 
decreasing and then increasing. However, 
in that case θ1 > 0.99 for all Pe, which is 
seemingly at odds with the evidence that 
endothelial injury can lead to proteinuria. 
Th us, case (2) is viable also, but appar-
ently only if W1 does not greatly exceed 
W2. Incidentally, the diff erence between 
the last two curves, which is magnifi ed as 
Pe increases, shows an advantage in plac-
ing the most selective layer upstream.
In summary, the finding that θ for 
various macromolecules decreases with 
increasing GFR offers clues about the 
dynamics of sieving in the multilayer 
glomerular capillary wall. It is generally 
consistent with the idea that both cell lay-
ers contribute to the observed size-selec-
tivity of the barrier.
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β2-microglobulin, a uremic toxin 
with a double meaning
B Canaud1,2, M Morena2, JP Cristol3 and D Krieter4
β2M is a strong and independent indicator of hemodialysis patient 
outcomes and an excellent surrogate for middle molecules, and 
deserves to be routinely monitored and incorporated into dialysis 
adequacy targets. β2M has a double meaning, reflecting both dialysis 
efficacy in terms of solute mass transfer and patient bioactivity. The 
work of Ward et al. in this issue warrants a study to test the hypothesis 
that long daily hemodiafiltration treatment would be the optimal renal 
replacement modality to improve dialysis patient outcomes.
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In this issue, Ward and coworkers1 
report an interesting study exploring the 
barriers to the reduction of circulating 
β2-microglobulin (β2M) levels in long-
term hemodialysis patients. By apply-
ing β2M kinetic modeling analysis to a 
group of dialysis patients, the authors 
determined that the limitation in β2M 
mass removal during post-dilution 
hemodiafi ltration (HDF) was mainly 
due to the patient body mass transfer 
resistance rather than the hemodiafi l-
ter clearance per se. Th is fi nding is not 
really new but is still crucial, as it illus-
trates the fact that the body clearance 
is not equivalent to the dialyzer clear-
ance. Th e diff erence between body and 
dialyzer mass transfer rates refl ects pre-
cisely the β2M mass transfer resistance 
resulting from the complex interaction 
of the patient–hemodialysis system. Th e 
limitation of the β2M mass removal dur-
ing an HDF session is due to the high 
intracorporeal mass transfer resistance 
that limits the access to β2M stores in the 
remote poorly perfused compartment. 
Th e β2M concentration gradient built 
during the dialysis session within these 
two compartments (superficial well-
perfused and remote poorly perfused) 
is referred to as the compartmentaliza-
tion eff ect. Th is apparent sequestration 
of β2M within the patient’s body occurs 
during high-effi  ciency HDF and resolves 
in post-dialysis by the rebound phe-
nomenon. Th e amplitude of the post-
dialysis rebound refl ects the intensity of 
the body concentration disequilibrium 
generated during the dialysis session.
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In this context, β2M kinetic modeling 
analysis appears to be quite helpful in 
designing the optimal renal replacement 
modality and in describing the complex 
behavior of middle-sized and large ure-
mic solutes in hemodialysis patients. In 
clinical practice, such kinetic analysis may 
serve also to identify the causes of limita-
tion of the removal of middle-sized sol-
utes in short dialysis treatment schedules.2 
Phosphate kinetics is a typical example 
of such a problem with an acute clinical 
relevance. Phosphate mass transfer per 
session remains desperately inadequate 
despite the extensive use of high-flux 
membrane and high-effi  ciency modalities. 
Limitation of the removal of phosphate is 
mainly due to its high body mass transfer 
resistance and is minimally aff ected by the 
dialyzer clearance. Reduced body clear-
ance of inorganic phosphate is due to the 
intracellular and mitochondrial location 
of this compound. Th is phenomenon has 
been well documented in a recent study 
showing that phosphate kinetics fits a 
four-compartment model with biphasic 
concentration changes during high-effi  -
ciency dialysis methods.3
Scientifi c evidence now supports the 
hypothesis that middle- and large-molecu-
lar-weight compounds that accumulate in 
chronic uremia might contribute to mor-
bidity and mortality of dialysis patients. In 
the early 1970s, Babb et al. formulated the 
‘middle molecules’ hypothesis to explain 
some unresolved manifestations of ure-
mia in patients treated by conventional 
hemodialysis. It was then postulated that 
the accumulation of middle and large 
molecules in hemodialysis patients treated 
with a hemodialyzer with low membrane 
permeability was responsible for specifi c 
complications such as pericarditis and/or 
neuropathy. Over the past two decades, 
this fascinating hypothesis has stimulated 
scientifi c clinical research and technical 
improvement in membrane and dia-
lyzer manufacturing. Tremendous work 
to isolate and identify middle-molecule 
compounds has been undertaken by sev-
eral groups, with limited success.4 Th e 
complexity of this task has led a group of 
experts to set up the European Uremic 
Toxin Work Group (EUTox), dedicated to 
breaking up and identifying these uremic 
toxins. At the same time, synthetic highly 
permeable (high-fl ux) membranes have 
been engineered, and hemodialyzers have 
been designed to increase the clearance of 
middle- and large-molecular-weight sol-
utes. High-fl ux membranes reduce signifi -
cantly the mortality in dialysis patients.5 
Enhancement of convective clearances 
has been applied in the clinic by means 
of hemofi ltration and hemodiafi ltration 
methods in order to increase the removal 
of large-molecular-weight solutes. Maxi-
mizing removal of middle-sized uremic 
toxins is a new goal that is manifested by 
the increase in prescription of high-fl ux 
hemodialyzers, a practice supported by 
the recently published European Best 
Practices Guidelines. This trend was 
clearly boosted aft er amyloidosis was diag-
nosed in long-term hemodialysis patients 
and β2M was identifi ed as the major com-
ponent of this amyloid tissue. Th e toxic 
role of middle-sized and large compounds 
in dialysis patients is supported by recent 
fi ndings of the EUTox group recognizing 
their heterogeneity and identifying their 
specifi c toxicity in uremic patients.6
Among these middle-sized toxins, β2M 
has emerged as a particularly interesting 
biomarker of morbidity and mortality in 
uremic patients.7 β2M is the marker of ref-
erence for middle-sized uremic toxins that 
is used to assess dialyzer performance and 
treatment effi  cacy schedule. β2M may be 
considered as a surrogate for middle mole-
cules in this case. β2M kinetic analysis also 
provides useful insight into the kinetics of 
middle and large molecules that are not 
measurable in the clinic. In this context, 
blood β2M kinetics should be considered 
as a complementary tool to optimize treat-
ment schedule, particularly for defi ning 
the frequency and duration of sessions.
Until recently, β2M was considered a 
prominent and pathogenic maker for β2M 
amyloidosis, a severe and disabling com-
plication observed in long-term dialysis 
patients. Th e relationship was established 
on the observation that a gradual rise 
in blood β2M concentrations occurs in 
chronic kidney failure patients and that, 
similarly, the prevalence of β2M amyloido-
sis increases with years spent on dialysis. 
Th is observation supports the fact that 
β2M and middle molecules accumulate 
in dialysis patients as a result of the loss 
of residual kidney function and the low 
β2M removal of low-fl ux hemodialysis. 
Although the exact mechanism by which 
the circulating β2M tends to deposit in tis-
sue and to polymerize in amyloid fi brils 
remains unclear, it has been clearly shown 
that this process requires several chemi-
cal modifi cations of the β2M. Th e uremic 
internal milieu, including the chronic 
microinflammation, the oxidative and 
carbonyl stress, and the cell phagocytosis 
defect, off ers a quite favorable environ-
ment for these modifi cations.8 In other 
words, the pathogenic role of β2M is 
correlated not simply to its high blood 
concentration but rather to the chemical 
abnormalities of the uremic environment 
that modify its reactivity. Th is is a very 
important fi nding suggesting that tox-
icity of β2M is strongly amplifi ed by an 
environment of infl ammation and oxida-
tive stress.
High blood β2M concentration has 
emerged very recently as an independent 
and strong indicator of poor outcomes 
in hemodialysis patients. A secondary 
analysis of the Hemodialysis (HEMO) 
Study has recently identified that β2M 
levels predict mortality in hemodialysis 
patients.9 The relative risk of all-cause 
mortality increased by 11% per 10-mg-
per-liter increase in β2M over a reference 
value of 27 mg per liter aft er adjustment 
for kidney urea clearance and time on 
dialysis. This study highlights the fact 
that, in time-dependent Cox regres-
sion models, blood β2M levels but not 
dialyzer β2M clearance are predictive of 
all-cause mortality. Such an observation 
means that blood β2M concentrations 
refl ect much more than a passive accu-
mulation of solute due to low β2M dia-
lyzer removal; rather, they are a mixed 
biomarker reflecting the poor hemo-
compatibility of the dialysis system, the 
unfavorable chemical environment, and 
the periodic cell activation. Interestingly, 
one can link this observation to the bet-
ter outcomes recently reported in chronic 
kidney disease patients treated with highly 
effi  cient HDF. Two large cohort studies of 
hemodialysis patients using Cox regres-
sion models have reported that the relative 
risk of all-cause mortality was reduced by 
35%–37% in patients treated with highly 
effi  cient HDF as compared with hemodi-
alysis aft er adjustment for age and main 
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comorbid conditions. By combining high 
diff usive and convective clearances with 
a low hemoincompatible profile, HDF 
off ers the best available method to date to 
reduce circulating β2M levels over a long 
period of time in dialysis patients.
Th ese recent fi ndings suggest that β2M 
is a strong biomarker of morbidity and 
mortality in hemodialysis patients. Pre-
dialysis blood β2M concentrations provide 
dual information, both on dialysis effi  cacy 
and on internal-milieu bioactivity.
Considering all these factors, it is obvi-
ous that the β2M kinetic analysis proposed 
by Ward and coworkers,1 based on on-line 
post-dilution HDF, is very well taken. In 
this study it is proved that the limitation of 
β2M mass removal in HDF is mainly due 
to the intercompartmental mass transfer 
resistance within the patient and is not 
a consequence of the low hemodiafi lter 
clearance. Th is study leaves us with four 
important messages: First, it confi rms that 
on-line HDF is the most effi  cient renal 
replacement therapy method to remove 
β2M and middle molecules, twice com-
pared with high-fl ux hemodialysis. Under 
highly effi  cient HDF operative conditions, 
the β2M clearance obtained was 73 ml per 
minute, which means that the β2M mass 
removed during the 4-hour session was 
close to 200 mg per session (600 mg per 
week). Second, the calculated intrac-
orporeal β2M clearance was 82 ml per 
minute, a value close to that of the dia-
lyzer clearance. Under these conditions, 
HDF induces an apparent and progressive 
sequestration of β2M in the remote poorly 
perfused compartment. Th ird, a simple 
weekly mass balance considering the β2M 
generation rate (0.136 mg per minute, 
1300 mg per week) and the β2M removal 
rate indicates that the weekly accumu-
lation was close to 700 mg. Fourth, to 
achieve a zero weekly β2M mass balance 
in anuric HDF patients, one must change 
the treatment schedule, by increasing the 
treatment duration (6 to 8 hours) and/or 
by increasing the frequency of sessions 
(daily HDF). Short daily hemofi ltration 
and HDF programs have been evaluated 
in several studies that have all underlined 
the power of daily treatment in increasing 
β2M removal capacity.10,11 Unfortunately, 
the impact of long daily HDF has not been 
tested to confi rm this hypothesis.
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